So ROCKY, what I hear you saying in your last paragraph, is what some of us have been suggesting for awhile to some poster dismay and that is a rs is necessary.
The hope has been that as we approach the release of Phase I/II data, an increase share price would lessen the rs ratio?, and pave the way for a better exchange and institutional investors.
I would like to cite again, my well worn mantra of the financial manipulative scum that are out there preying on these young biotechs through their manipulative action, including naked shorting.
This has been all well documented by reputable sources and there have been many convictions of guilty parties in the process, but no where enough, imo
So, for me. ACTC remains an incredibly sound young biotech investment, (but like most, always saddled with far too many OS necessary to stay alive,) if I can stomach all the daily shenanigans going on by the hedge funds and scared individual investors that are dropping the price down
Do you, or others have a more cogent assessment?.
